首页> 外文期刊>EBioMedicine >N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1
【24h】

N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1

机译:Trim7的N6-甲基腺苷改性通过BRMS1的普遍突出来积极地调节骨肉瘤中的肿瘤引发和化学抑制性

获取原文
           

摘要

Background Metastasis is the leading cause of death in patients with osteosarcoma. Some of these patients fail to respond to chemotherapy and die of metastasis within a short period. Therefore, it is important to identify novel biomarkers to improve the diagnosis and treatment of osteosarcoma. TRIM7 is a member of the tripartite motif (TRIM) family protein that is involved in various pathological conditions including cancer; however, its role in osteosarcoma remains elusive. Methods Cell proliferation, invasion and migration were measured by CCK-8 and Transwell. Immunoprecipitation and mass spectrometry analysis were used to identify candidate proteins associated with TRIM7. Immunoprecipitation, immunofluorescence, pull down and ubiquitination assay were performed to examine the regulation between TRIM7 and its candidate protein. m6A modification of TRIM7 was measured by RNA immunoprecipitation. Findings TRIM7 expression was upregulated in osteosarcoma tissues and was an independent risk factor in predicting poor prognosis. TRIM7 regulates osteosarcoma cell migration and invasion through ubiquitination of breast cancer metastasis suppressor 1 (BRMS1). Moreover, chemoresistance was readily observed in osteosarcoma cells and in patient-derived xenograft (PDX) mice with higher TRIM7 levels. Loss of TRIM7 m6A modification was observed in osteosarcoma tissues. METTL3 and YTHDF2 were the main factors involved in the aberrant m6A modification of TRIM7. Interpretation Overall, our findings show that TRIM7 plays a key role in regulating metastasis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. Funding This work was financially supported by grants of NSFC (81001192, 81672658 and 81972521) and National Key Research Project of Science and Technology Ministry (2016YFC0106204).
机译:背景技术转移是骨肉瘤患者死亡的主要原因。其中一些患者未能在短时间内对化疗进行反应和死亡。因此,重要的是识别新型生物标志物,以改善骨肉瘤的诊断和治疗。 Trim7是三方基质(修剪)家族蛋白的成员,这些蛋白质参与包括癌症的各种病理病症;然而,它在骨肉瘤中的作用仍然难以捉摸。方法通过CCK-8和Transwell测量细胞增殖,侵袭和迁移。免疫沉淀和质谱分析用于鉴定与TRIM7相关的候选蛋白。进行免疫沉淀,免疫荧光,下拉和泛素化测定以检查Trim7及其候选蛋白之间的调节。通过RNA免疫沉淀法测量Trim7的M6A改性。发现Trim7表达在骨肉瘤组织中令人兴奋地升高,是预测预后差的独立危险因素。 TRIM7通过乳腺癌转移抑制器1(BRMS1)来调节骨肉瘤细胞迁移和侵袭。此外,在骨肉瘤细胞和患者衍生的异种移植物(PDX)小鼠中容易观察化学渗透度,具有较高的TRIM7水平。在骨肉瘤组织中观察到TRIM7 M6A改性的丧失。 MetT13和Ythdf2是Aperrant M6A改性的主要因素。总体上,我们的研究结果表明,Trim7通过BRMS1的泛素化对骨肉瘤中的转移和化学抑制起作用的关键作用。这项工作的资金是由NSFC的补助金(81001192,81672658和81972521)和科学技术部的国家重点研究项目(2016YFC06204)的财务支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号